Cannabis Effects on Opioid Self-Administration
Key facts
- Who runs it
- Shanna Babalonis, PhD
- Where
- Lexington, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 30 people, planned
- Starts
- 30 Nov 2026
- Expected to end
- 30 Jul 2031
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Cannabis
- Placebo Cannabis
- Intranasal Opioid Agonist
- Oral Opioid Agonist
- Record updated
- 14 October 2026
Who can take part
- Age
- 18 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Participants with moderate to severe opioid use disorder who experience opioid withdrawal
- No allergies or adverse reactions to cannabis or opioids
- Willing to stay inpatient at the UK Hospital research center for approx. 6 weeks
Who cannot take part
- Individuals seeking treatment for opioid use disorder
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Where in United States
- University of Kentucky Center on Drug and Alcohol ResearchLexington, United StatesContact: Paul NuzzoNot yet recruiting
About the trial
What the trial wants to find out
The study will enroll participants with opioid use disorder and participants will reside at the University of Kentucky Hospital for this 6-week inpatient trial. During this time, double-blind doses of cannabis and opioids will be administered. The goal of the project is to determine if cannabis can alter the drive/desire to take opioids.
The 2 groups in the trial
- Active CannabisTreatment being tested
Participants receive active cannabis three times daily for approximately 16 days during one crossover treatment period. During this period, participants complete sample and self-administration sessions evaluating placebo and active intranasal opioid administration.
Treatment: Cannabis, Intranasal Opioid Agonist, and Oral Opioid Agonist
- Placebo CannabisPlacebo, for comparison
Participants receive placebo cannabis three times daily for approximately 16 days during one crossover treatment period. During this period, participants complete sample and self-administration sessions evaluating placebo and active intranasal opioid administration.
Treatment: Placebo Cannabis, Intranasal Opioid Agonist, and Oral Opioid Agonist
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Impact of Cannabis on Opioid Self-Administration
- Fit questions
- Built from NCT07668635, who can take part
- Record updated
- 14 October 2026